Imagine if after a serious accident, your damaged facial bones could be replaced with tissue made by your own cells. Or if you could pop a pill that could reprogram your immune system to fight a chronic disease, freeing you from a lifetime of medications. While both prospects sound futuristic, scientists and engineers at Johns Hopkins and elsewhere are working toward these and other advances in tissue engineering.

By launching AbMeta Therapeutics, a startup aimed at developing anti-metastatic therapies based on engineered antibodies, Denis Wirtz has served as a real-life example of the high value that Johns Hopkins places on entrepreneurship.

A new particle assembly technology created by Johns Hopkins engineers in partnership with experts from a biotechnology company is making it easier and more cost-efficient to produce viral vectors: engineered viruses that have been used to modify therapeutic cells to treat congenital and acquired diseases.

As a professional communicator, Amy Weldon understands the proverbial power of the pen — how choosing just the right word or phrase can not only educate and inform but also change minds and hearts. But Weldon is equally conversant with a different kind of power — one that comes from putting her body to the test lifting weights as heavy as 415 pounds.